Utility of CD3 and CD30 in Immunophenotyping of Lymphomas Among Sudanese Patients

Hussain Gadkarim Ahmed1, Tumadir Mohmmed Adam1, Nagla K. Basama2 and Ahmed Abdillah Agabeldoi2

1Department of Histopathology and Cytology, Faculty of Medical Laboratory Sciences, Khartoum, Sudan
2University of Gazira, Center of Bioscience and Biotechnology, Madani, Sudan
3University of Kordofan, Faculty of medicine, Obied, Sudan

Abstract

Background and Aims: Phenotypic analysis of lymphomas is now considered compulsory for precise classification which is the starting point for best possible patient management. The aim of this study was to investigate the frequencies of T cell (using CD3) and Hodkgin’s cell (using CD30) lymphomas in Sudan.

Methods: In this retrospective study, paraffin embedded tissue blocks from 62 patients with lymphomas and three patients with benign lymph proliferative disorders were studied. All of the 65 specimens were immunostained for CD3, only 30 specimens were immunostained for CD30 expression.

Results: Out of the 62 cases of lymphomas, 13 (21%) were cases of Hodkgin’s lymphoma and the remaining 49 (79%) were Non-Hodkgin’s lymphomas. Of the 62 cases immunostained for CD3 expression, 15 (24%) were identified as CD3-positive. Of the 30 cases immunostained for CD30 expression, 12 (40%) were demonstrated as CD30-positive, all of them from the cases of Hodkgin’s lymphomas.

Conclusion: There is high frequency of T-cell lymphomas among Sudanese lymphoma’s patients. CD30 marker has a reasonable specificity and sensitivity measures as a marker for identifying Hodkgin’s lymphomas. Studies for immunophenotyping of lymphoma with extra markers are highly recommended.

Introduction

Cell marker analysis helps to determine whether the lymphoid cell population is composed of many different cells or if there is only one cell type present. Cell marker analysis can help determine whether B cells or T cells are present. CD3 is a human cell surface glycoprotein complex consisting of at least five different polypeptide chains [1]. These chains are closely associated with each other and also with T cell antigen receptor, and are involved in signal transduction following binding of antigen receptor. The CD3 antigen is expressed during thymopoiesis and on mature T cells in the periphery. It is also present in the majority of T cell Chronic Lymphocytic Leukemia (CLL) and T lymphomas and in approximately 70% of T cell acute lymphoblastic leukemia (ALL). Cytoplasmic CD3 was demonstrated in 95% of thymocytes and in all T-ALL including those in which surface membrane CD3 was absent [2,3]. In this study we used CD3 as a marker to distinguish between T- cell lymphomas and B cell lymphomas.

CD30 is a surface marker for neoplastic cells of Hodkgin’s lymphoma and shows sequence homology to members of the tumor necrosis factor (TNF) receptor super family. This receptor is expressed by activated, but not by resting, T and B cells [4]. Immunohistochemical evaluation of CD30 expression is commonly performed in the assessment of hematopoietic disorders and germ cell tumors. Immunoreactivity was observed in all cases of classical Hodkgin lymphoma, anaplastic large cell lymphoma [5]. The current study used CD30 as a marker with the presence of Reed-Sternberg cells to group the classical Hodkgin’s lymphomas.

However, disturbed expression of the TCR/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations was reported [6]. Severely altered expression of the T-cell receptor/CD3 complex, T-cell receptor-associated transcription factors and signal transduction molecules is a common characteristic of systemic and cutaneous CD30+ lymphoproliferations, although the clinical behavior of these entities is very different [7].

Non Hodkgin lymphomas are the most common lymphomas in the Sudan, as well as, relatively high frequency of T-cell lymphomas. Recent studies from developed countries have shown differences in survival for the different immunophenotypes. Such studies are lacking in the Sudan where diagnosis is largely dependent on morphology alone. Although, there are many markers available to distinguish T-cell and B cell lymphoma types as well as Hodkgin’s lymphoma types, but we tested these two markers as they are most frequently used markers in this context in Sudanese Immunohistochemical Laboratories. Therefore, in this study we are trying to determine the prevalence of different types of lymphoma in Sudan population, as well as possible sub classification of lymphomas in T cell and B cell types or Hodkgin’s and Hodkgin’s types in the Sudan.

Methodology

In this retrospective study, paraffin embedded tissue blocks from 62 patients with lymphomas and three patients with benign lymph proliferative disorders were retrieved from two histotechnology laboratories, as indicated in Table 1. These were all the available continuous cases seen at our Histotechnology laboratories (during a period of 10 years). Clinical and pathologic information was obtained...

by review of patients’ medical records and surgical pathology reports and by review of H&E-stained sections of the lymphomas. One pathologist retrospectively reviewed the H&E-stained sections and two CD immunostains. All specimens which were obtained from cases of lymphomas and benign lymph proliferative disorders were immunostained for CD3 expression, hence, only 30 specimens out of the 62 cases of lymphomas were immunostained for CD30 expression.

Lymphoid tissue biopsies were fixed in neutral buffered formalin and embedded in paraffin. Sections of formalin-fixed, paraffin-embedded tissue (5 µm) were tested for the presence of CD3 and CD30 (Clone F7.2.38 and Ber-H2; DAKO, Denmark) using an avidin biotin-complex technique and water bath heat-induced antigen retrieval. An avidin-biotinylated enzyme complex kit (DAKO LSAB2 Denmark) was used. Hematoxylin was used as counterstain. Appropriate positive controls were sections of Tonsil, previously used to determine the best dilution of antibody and to optimize the IHC technique. This positive control is run with all sections on which CD3 or CD30 immunohistochemistry is requested, so that its use is standardized and its specificity is known. Positive control slides are reviewed with each run to note any decreased sensitivity in any particular run. Negative controls had primary antibody replaced by buffer.

Immunohistochemistry staining was done adopting procedure described by Ahmed et al. [8] Sections were deparaffinized and rehydrated, then steamed in citrate buffer (pH 6) for 25 minutes and cooled for 20 minutes before immunostaining. All tissues were exposed to 3% hydrogen peroxide for 5 minutes, primary antibody (CD3 or CD30, DAKO, Denmark) for 60 minutes, biotinylated secondary linking antibody for 25 minutes, streptavidin enzyme complex for 25 minutes, diaminobenzidine as chromogen for 5 minutes, and hematoxylin as counterstain for 2 minutes. These incubations were performed at room temperature; between incubations, sections were washed with Tris-Buffered Saline buffer (DAKO). Ethical consent: Permission to carry out the study was obtained from the Kordofan University Faculty of Medicine Research Committee.

Results

Of the 62 cases of lymphomas, 13(21%) were patients with Hodgkin’s lymphomas and the remaining 49 (79%) were Non-Hodgkin’s lymphomas of which 5(10%) were cases of Burkett’s lymphomas. The majority of patients were male (77%). The mean age at diagnosis was 35 years (range, 2 to 80 years).

<table>
<thead>
<tr>
<th>Lymphatic disorder</th>
<th>Frequency</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hodgkin’s lymphoma</td>
<td>13</td>
<td>20</td>
</tr>
<tr>
<td>Non-Hodgkin’s lymphoma</td>
<td>44</td>
<td>67</td>
</tr>
<tr>
<td>Burkitt’s lymphoma</td>
<td>5</td>
<td>8</td>
</tr>
<tr>
<td>Benign lymphoproliferative</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Total</td>
<td>65</td>
<td>100</td>
</tr>
</tbody>
</table>

Table 1: Distribution of the study population by benign proliferative disorders.

Of the 62 tissue sections immunostained for CD3 expression, 15(24%) were identified as CD3-positive. Of the 30 cases immunostained for CD30 expression, 12(40%) were demonstrated as CD30-positive. All of the 13(21%) cases of Hodgkin’s lymphomas were immunostained for CD30 expression. Out of the 13 cases of Hodgkin’s lymphomas, CD30 positive expression was identified in 11(84%) cases. Out of the remaining 17 cases of Non-Hodgkin’s that were immunostained for CD30, only one (6%) was found as CD30 positive specimens of Non-Hodgkin’s lymphomas. The three cases of benign lymph proliferative disorders were only immunostained for CD3 and all were found as, CD3-negative. Of the 13 specimens of Hodgkin’s lymphomas, only one (7.7%) specimen was found CD3 positive, hence, out of 49 specimens of Non-Hodgkin’s lymphomas, 14 (28.6%) specimens were found CD3 positive, as shown in Table 2. These measures revealed sensitivity and specificity for CD30 constituting 84% and 94% respectively, for identifying of Hodgkin’s lymphoma.

Discussion

Histopathological examination remains fundamental for diagnosis and classification of malignant lymphomas, but poses problems when characteristic features of specific lymphoma are not present. This raise up the value of immunohistochemistry. Experience with immunohistochemistry in developing countries is limited due to cost. Therefore, in this study, we have only used a monoclonal antibody to CD3 effective in paraffin sections to identify T cell lymphomas, and antibody to CD30 to identify Hodgkin’s lymphoma. Accordingly, CD3 + was representing 24% which was very high in relation to what was reported in the literature worldwide. In a study from the Sudan most cases of Burkett’s lymphoma occurred in Southern Sudan. It is concluded that geographic and racial factors play important roles in determining the frequency and pattern of neoplasms in the Sudan [9]. Non-Hodgkin’s lymphoma (CD30-ve) is the most common immunophenotype in the Sudan, which represented 79%, according to the histological evidences. However, up to now there is no detailed study investigated the immunophenotyping of lymphomas in the Sudan. Most available literature from the Sudan dealt with Burkett’s lymphoma. During the period 1962-80 thirty-five cases of Burkett’s lymphoma were seen and examined histologically in Khartoum, Sudan [10,11].

A retrospective study was performed dealing with clinical and histopathological aspects of Hodgkin’s disease in patients presenting to the Radiation and Isotopes Centre of Khartoum (RICK) during the period from January 1984 to January 1989. A total of 105 patients were studied; this number accounted for 30.6% of all lymphoma patients and 2.0% of all cancers seen at RICK during the same period [12].

There is paucity of information on childhood cancer from the Sudan. Data was obtained from the hospital registry for the period May 1999 to June 2007 on all paediatric patients presenting to the Institute of Nuclear Medicine and Oncology, University of Gezira, Wad Madani, Sudan. There were 322 children with cancer during this time period with a male: female ratio of 1.6:1. Lymphomas (111, 35%), leukaemia (83, 26%) and Wilms’ tumor (43, 13%) were the three most common groups of tumors. Thirty percent of all lymphomas were Burkett’s lymphoma; 3.4% of all childhood cancer cases were nasopharyngeal carcinomas [13].

Phenotyping of lymphomas is considered mandatory for subsequent best patient management. This is now carried out in most cases using a range of antibodies recognizing T and B cells in paraffin sections. Although, there are many T-cell-specific markers

<table>
<thead>
<tr>
<th>Lymphoma type</th>
<th>CD3 (Clone F7.2.38)</th>
<th>Total</th>
<th>CD30 (Clone Ber-H2)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hodgkin’s</td>
<td>12</td>
<td>13(p&lt;0.01)</td>
<td>2</td>
<td>13(p&lt;0.01)</td>
</tr>
<tr>
<td>Non-Hodgkin’s</td>
<td>14</td>
<td>35</td>
<td>65</td>
<td>12(40%)</td>
</tr>
<tr>
<td>Benign</td>
<td>5</td>
<td>3</td>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>15(24%)</td>
<td>50</td>
<td>85</td>
<td>18(24%)</td>
</tr>
</tbody>
</table>

Table 2: Immunoeexpression of CD3 and CD30 in Hodgkin’s, Non-Hodgkin’s lymphoma and benign lymph proliferative disorders.

References

(Continuation...)


